Yuan Zhi
Stock Analyst at B. Riley Securities
(0.18)
# 4,091
Out of 4,784 analysts
21
Total ratings
15%
Success rate
-33.51%
Average return
Main Sectors:
Stocks Rated by Yuan Zhi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HYPR Hyperfine | Maintains: Buy | $1.5 → $1.2 | $0.72 | +66.67% | 1 | Mar 20, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $15 | $5.40 | +177.78% | 1 | Mar 12, 2025 | |
| TNGX Tango Therapeutics | Maintains: Buy | $16 → $8 | $1.47 | +444.22% | 2 | Nov 11, 2024 | |
| MIR Mirion Technologies | Initiates: Buy | $14 | $14.63 | -4.31% | 1 | Sep 26, 2024 | |
| AGEN Agenus | Maintains: Buy | $42 → $18 | $1.60 | +1,025.00% | 2 | Aug 14, 2024 | |
| CYRX Cryoport | Upgrades: Buy | $19 → $15 | $6.09 | +146.31% | 4 | Jul 31, 2024 | |
| CTSO Cytosorbents | Reiterates: Buy | $3 | $1.00 | +200.00% | 1 | May 15, 2024 | |
| CATX Perspective Therapeutics | Maintains: Buy | $12 → $17 | $2.20 | +672.73% | 2 | Apr 9, 2024 | |
| AZTA Azenta | Maintains: Buy | $61 → $79 | $34.61 | +128.26% | 3 | Feb 1, 2024 | |
| ATNM Actinium Pharmaceuticals | Maintains: Buy | $20 → $16 | $1.81 | +783.98% | 4 | Dec 11, 2023 |
Hyperfine
Mar 20, 2025
Maintains: Buy
Price Target: $1.5 → $1.2
Current: $0.72
Upside: +66.67%
Radiopharm Theranostics
Mar 12, 2025
Initiates: Buy
Price Target: $15
Current: $5.40
Upside: +177.78%
Tango Therapeutics
Nov 11, 2024
Maintains: Buy
Price Target: $16 → $8
Current: $1.47
Upside: +444.22%
Mirion Technologies
Sep 26, 2024
Initiates: Buy
Price Target: $14
Current: $14.63
Upside: -4.31%
Agenus
Aug 14, 2024
Maintains: Buy
Price Target: $42 → $18
Current: $1.60
Upside: +1,025.00%
Cryoport
Jul 31, 2024
Upgrades: Buy
Price Target: $19 → $15
Current: $6.09
Upside: +146.31%
Cytosorbents
May 15, 2024
Reiterates: Buy
Price Target: $3
Current: $1.00
Upside: +200.00%
Perspective Therapeutics
Apr 9, 2024
Maintains: Buy
Price Target: $12 → $17
Current: $2.20
Upside: +672.73%
Azenta
Feb 1, 2024
Maintains: Buy
Price Target: $61 → $79
Current: $34.61
Upside: +128.26%
Actinium Pharmaceuticals
Dec 11, 2023
Maintains: Buy
Price Target: $20 → $16
Current: $1.81
Upside: +783.98%